Immuneering Corporation is providing updates on its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients, indicating progress in its research and development efforts.

PolyPid is set to report topline data from the SHIELD II Phase 3 trial for D-PLEX100, indicating significant progress in its development pipeline aimed at preventing surgical site infections. The ...

Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to Skye Biosciences conference call to discuss Phase IIa top line clinical trial results. I would now ...

Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, ...